SCHEMBL322652

SCHEMBL322652

C=C(C)C(=O)OC(C)O[Si](C)(C)OC(C)OC(=O)C(=C)C

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.39
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63713 0.88 TSHR (0.41) TSHRALDH1A1THRB
SCHEMBL952948 0.88 TSHR (0.41) TSHRALDH1A1THRB
SCHEMBL5702010 0.86 TSHR (0.38) TSHRALDH1A1THRB
SCHEMBL65534 0.85 TSHR (0.42) TSHRALDH1A1THRB
SCHEMBL538063 0.82 TSHR (0.50) TSHRALDH1A1THRB
SCHEMBL2028634 0.81 TSHR (0.36) TSHRALDH1A1
SCHEMBL4207433 0.81 TSHR (0.40) TSHRALDH1A1THRB
SCHEMBL9559905 0.80 ALDH1A1 (0.41) TSHRALDH1A1
SCHEMBL9560048 0.80 ALDH1A1 (0.41) TSHRALDH1A1
SCHEMBL6904341 0.80 TSHR (0.48) TSHRALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070281870-A1 Stimuli-degradable gels HALLIBURTON ENERGY SERVICES, INC. 2007-12-06 US claimed
US-20240189417-A1 SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-06-13 US disclosed
US-20240059846-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES ALLARTA LIFE SCIENCE INC (CA) 2024-02-22 US disclosed
EP-4255965-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES Allarta Life Science Inc. (CA) 2023-10-11 EP disclosed
EP-4180057-A1 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES GlaxoSmithKline Biologicals S.A. (BE) 2023-05-17 EP disclosed
WO-2023031855-A1 SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-03-09 WO disclosed
US-20220192997-A1 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-06-23 US disclosed
WO-2022120478-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES ALLARTA LIFE SCIENCE INC. (CA) 2022-06-16 WO disclosed
EP-4005592-A1 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES GlaxoSmithKline Biologicals S.A. (BE) 2022-06-01 EP disclosed
US-11291635-B2 Virion-like delivery particles for self-replicating RNA molecules GLAXOSMITHKLINE BIOLOGICAL SA (BE) 2022-04-05 US disclosed
EP-3115061-A1 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES GlaxoSmithKline Biologicals SA (BE) 2017-01-11 EP disclosed
EP-2900783-A1 DEHYDRATED GEL COMPOSITIONS AND METHODS OF USING THE SAME Halliburton Energy Services, Inc. (US) 2015-08-05 EP disclosed
US-20130195968-A1 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES NOVARTIS AG (CH) 2013-08-01 US disclosed
EP-2590676-A2 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES Novartis AG (CH) 2013-05-15 EP disclosed
WO-2012006376-A2 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES NOVARTIS AG (CH) 2012-01-12 WO disclosed
WO-2009132206-A1 COMPOSITIONS AND METHODS FOR INTRACELLULAR DELIVERY AND RELEASE OF CARGO LIQUIDIA TECHNOLOGIES, INC. (US) 2009-10-29 WO disclosed
US-7306040-B1 Stimuli-degradable gels HALLIBURTON ENERGY SERVICES, INC. (US) 2007-12-11 US disclosed
US-20070277981-A1 STIMULI-DEGRADABLE GELS HALLIBURTON ENERGY SERVICES, INC. 2007-12-06 US disclosed
US-20070281870-A1 Stimuli-degradable gels HALLIBURTON ENERGY SERVICES, INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240189417-A1 SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS NSUN2, NSUN3, RNMT TSHR 2502/4885ALDH1A1 3328/4885THRB 2709/4885
US-20240059846-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES LTA, VCL, HBB TSHR 4092/4885ALDH1A1 507/4885THRB 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.